Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$66.82 USD
+1.25 (1.91%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $66.82 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Cytokinetics (CYTK) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$93.38 | $122.00 | $71.00 | 39.75% |
Price Target
Based on short-term price targets offered by 16 analysts, the average price target for Cytokinetics comes to $93.38. The forecasts range from a low of $71.00 to a high of $122.00. The average price target represents an increase of 39.75% from the last closing price of $66.82.
Analyst Price Targets (16)
Broker Rating
Cytokinetics currently has an average brokerage recommendation (ABR) of 1.44 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 18 brokerage firms. The current ABR compares to an ABR of 1.44 a month ago based on 18 recommendations.
Of the 18 recommendations deriving the current ABR, 13 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 72.22% and 11.11% of all recommendations. A month ago, Strong Buy made up 72.22%, while Buy represented 11.11%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 13 | 13 | 13 | 13 | 12 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.44 | 1.44 | 1.44 | 1.44 | 1.47 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/9/2024 | Raymond James | Sean Mccutcheon | Moderate Buy | Moderate Buy |
4/9/2024 | Needham & Company | Serge Belanger | Moderate Buy | Moderate Buy |
4/8/2024 | Truist Securities | Srikripa Devarakonda | Strong Buy | Strong Buy |
3/6/2024 | Mizuho SecuritiesUSA | Salim Syed | Strong Buy | Strong Buy |
2/29/2024 | Cantor Fitzgerald & Co | Charles C Duncan | Strong Buy | Strong Buy |
2/28/2024 | Piper Sandler | Yasmeen Rahimi | Strong Buy | Strong Buy |
2/28/2024 | H.C. Wainwright & Co. | Joseph Pantginis | Strong Buy | Strong Buy |
2/16/2024 | JMP Securities | Jason N Butler | Strong Buy | Strong Buy |
11/7/2023 | B. Riley Securities | Mayank Mamtani | Strong Buy | Strong Buy |
8/15/2023 | SVB Securities | Roanna Ruiz | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.44 |
ABR (Last week) | 1.44 |
# of Recs in ABR | 18 |
Average Target Price | $93.38 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 69 of 252 |
Current Quarter EPS Est: | -1.16 |